arrow
J

Jesús García-Donás

centro integral oncologico clara campal hm ciooc
H指数:35
被引数:9,877

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)

PD-L1在采用抗血管生成一线药物治疗转移性肾细胞癌(mRCC)患者中的预后价值(PROANG-SOGUG研究)

2026-09-280
PRE
External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy

S-GRAS评分在预测肾上腺皮质癌患者复发中的外部验证:对辅助米托坦治疗的启示

2025-08-140
PRE
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial

Rucaparib用于铂敏感、复发性卵巢癌的维持治疗:III期、随机、安慰剂对照ARIEL3试验的最终结果

2025-06-170
OA
Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry
2025-02-140
OA
CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds
2025-01-080
OA
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study
2024-08-120
PRE
Efficacy and safety of ceralasertib in the PLANETTE study in patients (pts) with ATM-altered advanced solid tumors (ASTs) or metastatic castration-resistant prostate cancer (mCRPC)
2024-04-050
PRE
Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancer

腹膜液来源的小细胞外囊泡的蛋白质组学特征与卵巢癌患者预后相关

2024-04-023
OAAI
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201

Pemigatinib治疗转移性或手术不可切除的尿路上皮癌伴FGF/FGFR基因组改变: 来自FIGHT-201的最终结果

2024-02-018
OAAI
Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution
2023-04-184
OAAI
Management of Fibroblast Growth Factor Inhibitor Treatment- emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
2023-04-017
OAAI
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
2022-04-0112
OAAI